Bacterial endotoxin testing for pharmaceutical drug products, medical devices, packaging systems, and raw materials. We design and execute programs that account for matrix interference, extraction geometry, and regulatory expectations, delivering results that are technically sound and audit-ready.
Endotoxin testing is one of the most consequential safety tests in pharmaceutical and medical device manufacturing. Endotoxins (lipopolysaccharides shed from the outer membrane of gram-negative bacteria) are pyrogenic even at trace levels and can cause serious adverse reactions in patients. Detecting them reliably is not optional; it’s a core release and safety requirement.
The challenge is that endotoxin testing is also one of the most interference-prone assays in the regulated laboratory. Products, materials, and device extracts can inhibit or enhance the LAL reaction, producing false negatives or false positives if the method hasn’t been properly validated for the specific matrix. A result is only meaningful if the method has been shown to work under the actual test conditions.
We build programs around that reality.
What We Test
We support endotoxin testing programs across a broad range of product types and testing contexts:
Medical devices: finished devices, device components, fluid path systems, and implantables requiring extraction-based testing per ISO 11135 and FDA guidance
Drug products: parenteral drug products, ophthalmic preparations, and other products with compendial endotoxin limits
Raw materials and excipients: incoming material testing to support supply chain control and batch release
Packaging and container closure systems: vials, stoppers, prefillable syringes, cartridges, and other primary packaging components in contact with sterile drug products
Process equipment and utilities: water for injection (WFI), purified water, and equipment surfaces where endotoxin control is part of the manufacturing program
LAL Methods: Gel Clot, Turbidimetric, and Chromogenic
USP <85> describes the Limulus Amebocyte Lysate (LAL) test as the primary compendial method for bacterial endotoxin testing. LAL reagent, derived from the blood of horseshoe crabs, reacts with endotoxin to produce a detectable response, the basis of three distinct methodologies:
Gel clot is the simplest and most established approach. The reaction produces a visible clot at or above the endotoxin threshold. It’s qualitative or semi-quantitative and remains widely used for its simplicity and robustness.
Turbidimetric LAL measures the increase in turbidity as the clotting cascade proceeds. Quantitative results are generated from a standard curve, and the method offers a broad dynamic range suitable for products requiring precise quantitation.
Chromogenic LAL uses a synthetic peptide substrate that releases a yellow color upon endotoxin-driven enzyme activation. Like turbidimetric, it’s quantitative and well-suited to complex programs requiring high sensitivity or automation.
Method selection depends on the product matrix, required sensitivity, throughput, and regulatory context. We work with clients to select the appropriate approach at program outset, not after a method failure.
Recombinant Factor C (rFC)
Recombinant Factor C methods, including the monocyte activation test (MAT) and rFC-based assays described in USP <86> and EP 2.6.30, offer an alternative to horseshoe crab-derived LAL reagent. These methods are gaining regulatory acceptance and eliminate dependence on a biological marine resource.
We support rFC testing as part of programs where regulatory strategy, sustainability commitments, or supply chain considerations make it the preferred approach. For most clients, LAL remains the primary method, but we’re equipped to discuss the tradeoffs and support a transition if that’s the direction.
Interference: The Problem Most Labs Understate
The validity of any endotoxin result depends on a fundamental condition: the LAL reaction must be neither inhibited nor enhanced by the product or extract being tested. USP <85> requires that this be demonstrated through a positive product control (PPC), a spiked sample run alongside every test to confirm acceptable recovery.
When inhibition or enhancement is present, the standard response is dilution. But dilution has limits, particularly for products with low endotoxin limits, where diluting past the point of interference also dilutes past the point of detection. This creates a genuine analytical challenge that requires a real solution, not a workaround.
We have direct, extensive experience with interference-prone matrices across parenteral products, device extracts, and complex packaging components. Our approach includes:
- Systematic inhibition/enhancement screening at program setup
- Evaluation of dilution strategy against the maximum valid dilution (MVD)
- Alternative approaches where dilution alone is insufficient: pH adjustment, heat treatment, enzymatic processing, chelation, and validated extraction modifications.
- Full documentation of the interference evaluation for regulatory submission
If a product has failed endotoxin method validation elsewhere, that’s exactly the kind of program we’re set up to take on.
Medical Device Extraction Testing
Endotoxin testing for medical devices requires extraction of the device or device component prior to testing, a step that introduces variables not present in simple liquid matrices. Extraction conditions, geometry, solvent, time, temperature, and agitation all affect endotoxin recovery, and the extraction method must be validated as part of the overall test program.
We support device extraction programs including:
Fluid path extraction: circulating extraction fluid through the internal surfaces of tubing sets, catheters, IV delivery systems, and other devices with patient-contacting fluid pathways
Full immersion extraction: complete submersion of device components for surface endotoxin recovery
Rinse extraction: direct rinsing of device surfaces or lumens where fluid path access is limited
Extraction parameters are selected based on device geometry, intended use, and applicable FDA and ISO guidance. We document the rationale for extraction conditions as part of the test record.
Program Design
Endotoxin limits: we help clients establish or verify endotoxin limits appropriate to the product type, route of administration, patient weight-based dosing calculations (K/M), and applicable pharmacopeial or FDA requirements
Sampling strategy: incoming material testing, in-process controls, and release testing designed around your manufacturing workflow
Water system support: endotoxin testing integrated with broader utility monitoring programs for WFI and purified water systems
Investigation and OOS support: when results exceed limits or spike unexpectedly, we support investigation, retest strategy, and root cause documentation
Audit-ready documentation: results reported with standard curve data, PPC recovery, reagent lot information, and full traceability
Standards and Regulatory Framework
Our endotoxin testing programs are performed in alignment with:
- USP <85> Bacterial Endotoxins Test
- USP <86> Monocyte Activation Test
- EP 2.6.14 Bacterial Endotoxins / EP 2.6.30 Monocyte Activation Test
- FDA Guidance for Industry: Pyrogen and Endotoxins Testing
- ISO 11135 (sterilization and endotoxin considerations for medical devices)
- 21 CFR 211 cGMP expectations
CLOSING / CTA
Let’s talk about your endotoxin program
Whether you’re establishing a new testing program, working through an interference problem, or need extraction testing for a medical device submission, we’re equipped to help, from method development through routine release.
[Contact us] [Request a consultation]
